Survival of metastatic germ cell cancer patients assessed by international germ cell consensus classification in Japan

Japanese Journal of Clinical Oncology

Volumn 38, Issue 4, 2008, Pages 281-287

  Shintaku, Ichiro ^a   Satoh, Makoto ^a   Okajima, Eijiro ^b   Fujimoto, Hiroyuki ^b   Kamoto, Toshiyuki ^c   Ogawa, Osamu ^c   Kawai, Koji ^d   Akaza, Hideyuki ^d   Tsukamoto, Taiji ^e   Naito, Seiji ^f   Miki, Tsuneharu ^g   Arai, Yoichi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

^g KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Etoposide; Germ cell tumor; IGCC classification; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; IFOSFAMIDE; PEPLEOMYCIN; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER SURVIVAL; CHORIOCARCINOMA; CONFIDENCE INTERVAL; CONSENSUS; CONTROLLED STUDY; EMBRYONAL CARCINOMA; FOLLOW UP; GERM CELL TUMOR; HIGH RISK POPULATION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; OVERALL SURVIVAL; PROGNOSIS; SEMINOMA; STATISTICAL SIGNIFICANCE; TERATOMA; YOLK SAC TUMOR;

ADOLESCENT; ADULT; AGED; CHORIOCARCINOMA; DISEASE-FREE SURVIVAL; ENDODERMAL SINUS TUMOR; HUMANS; JAPAN; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS; SEMINOMA; SURVIVAL RATE; TERATOMA; TESTICULAR NEOPLASMS;

EID: 42549123357     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn009     Document Type: Article

References (11)

1. Einhorn LH. Treatment of testicular cancer: A new and improved model. J Clin Oncol 1990;8:1777-81.
2. The International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.
3. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316:1435-40.
4. Miki T, Nakao M. Current status and future perspectives in the treatment of advanced testicular cancer. Int J Urol 2002;9:1-10.
5. Kawai K, Hinotsu S, Oikawa T, Sekido N, Hattori K, Miyanaga N, et al. Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor. Jpn J Clin Oncol 2006;36:723-30.
6. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci USA 2002;99:4592-5.
7. Muramaki M, Hara I, Miyake H, Yamada Y, Kawabata G, Kamidono S. Advances in the management of non-seminomatous germ cell tumors during the cisplatin era: A single-institution experience. Int J Urol 2004;11:768-73.
8. van Dijk MR, Steyerberg EW, Habbema JD. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. Eur J Cancer 2006;42:820-6.
9. Mazumdar M, Bajorin DF, Bacik J, Higgins G, Motzer RJ, Bosl GJ. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 2001;19:2534-41.
10. Kollmannsberger C, Nichols C, Meisner C, Mayer F, Kanz L, Bokemeyer C. Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: An explorative analysis using cart modeling. Ann Oncol 2000;11:1115-20.
11. van Dijk MR, Steyerberg EW, Stenning SP, Habbema JD. Identifying subgroups among poor prognosis patients with nonseminomatous germ cell cancer by tree modelling: A validation study. Ann Oncol 2004;15:1400-5.